➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Boehringer Ingelheim
Merck
Mallinckrodt
McKinsey

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Magnesium Sulfate In Dextrose 5% In Plastic Container

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002146 Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study Completed Astra USA Phase 4 1969-12-31 To determine whether acute ionized hypomagnesemia and hypocalcemia immediately following foscarnet infusions can be lessened or eliminated by prior infusion of magnesium sulfate. To determine whether reductions in ionized magnesium, ionized calcium, and parathyroid hormone levels following foscarnet infusions are lessened by preinfusion of magnesium sulfate. To evaluate the safety of intravenous magnesium sulfate prior to foscarnet infusion by monitoring blood pressure, heart rate, and heart rhythm. To characterize the effect of magnesium sulfate on foscarnet blood levels and urinary excretion of calcium, magnesium, phosphate, and foscarnet.
NCT00004399 Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia Completed University of Utah N/A 1995-09-01 OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004399 Randomized Study of Nimodipine Versus Magnesium Sulfate in the Prevention of Eclamptic Seizures in Patients With Severe Preeclampsia Completed FDA Office of Orphan Products Development N/A 1995-09-01 OBJECTIVES: I. Determine the effectiveness of nimodipine versus magnesium sulfate in the prevention of eclamptic seizures in patients with severe preeclampsia.
NCT00004730 Magnesium Sulfate For Brain Injury Completed University of Washington Phase 3 1998-08-01 The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the survivors' mental and psychological functioning, including the ability to return to daily life, live independently, and return to work or school.
NCT00007033 Study of Magnesium Sulfate in Children With Reduced Bone Density Secondary to Chronic Cholestatic Liver Disease Completed Children's Hospital Medical Center, Cincinnati N/A 2000-10-01 OBJECTIVES: I. Determine the role of magnesium deficiency in the pathogenesis of decreased serum vitamin D and reduced bone density in children with chronic cholestatic liver disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Magnesium Sulfate In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Magnesium Sulfate In Dextrose 5% In Plastic Container
Intervention Trials
Postoperative Pain 17
Preeclampsia 11
Asthma 8
Pain 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Magnesium Sulfate In Dextrose 5% In Plastic Container
Intervention Trials
Pain, Postoperative 27
Pre-Eclampsia 23
Obstetric Labor, Premature 13
Asthma 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Magnesium Sulfate In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Magnesium Sulfate In Dextrose 5% In Plastic Container
Location Trials
United States 113
Egypt 50
Brazil 16
Canada 11
Korea, Republic of 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Magnesium Sulfate In Dextrose 5% In Plastic Container
Location Trials
California 8
Ohio 8
New York 8
Pennsylvania 7
Illinois 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Magnesium Sulfate In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Magnesium Sulfate In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Phase 4 59
Phase 3 36
Phase 2/Phase 3 16
[disabled in preview] 34
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Magnesium Sulfate In Dextrose 5% In Plastic Container
Clinical Trial Phase Trials
Completed 75
Not yet recruiting 64
Recruiting 57
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Magnesium Sulfate In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Magnesium Sulfate In Dextrose 5% In Plastic Container
Sponsor Trials
Assiut University 24
Cairo University 13
Seoul National University Bundang Hospital 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Magnesium Sulfate In Dextrose 5% In Plastic Container
Sponsor Trials
Other 268
Industry 10
NIH 10
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Boehringer Ingelheim
Johnson and Johnson
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.